Genmab — Maj 2019

[lahn1]

[E_L]

so next one to expect into clinic DuoHexaBody-CD37 ? http://www.bloodjournal.org/content/132/Suppl_1/4170?sso-checked=true http://www.haematologica.org/content/early/2019/02/15/haematol.2018.207266.full.pdf+html

[Solsen]

Fredagshumor

[Bulder]

.. or the other BioNtech thing PD-L1x4-1BB

[Sukkeralf]

That one is already on clinical trials

[E_L]

shame on you for missing that
Bulder

[Bulder]

soon too old to keep up the speed

[Bulder]

When did that happen?

[E_L]

about 2 weeks ago

[Sukkeralf]

april

[Sukkeralf]

301 Moved Permanently

(www.clinicaltrials.gov)

[Bulder]

ok, they haven't updated their homepage

[Sukkeralf]

Mon 4-1BB delen er den samme i disse to bispecifikke antistoffer

[Bulder]

de skriver om begge: Conditionally activates T cells

[Sukkeralf]

Ja så T-cellerne kun aktiveres i nærområdet af de solide tumorer

[Bulder]

Som de skriver i den artikel, du linkede til: Such compounds are usually designed to be inactive until binding the tumor
antigen, thereby localizing immune stimulation to the tumor environment, while minimizing
immune activation elsewhere.

[Sukkeralf]

Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

(www.fiercebiotech.com)

[Bulder]

Lige vand på Solsens mølle. Car-t holder ikke i længden.

[Solsen]

BCMA target er heller ikke med durable responses.

[peter12]

Lidt om samme emne https://www.medpagetoday.com/hematologyoncology/myeloma/79611